• Roche reported positive interim Phase III data for Genentech’s sefaxersen in adults with primary IgA nephropathy.
• The trial met its primary goal, showing a meaningful reduction in protein in urine versus placebo, supporting potential disease-slowing benefit.
• Results have not yet been presented; the interim analysis is slated for an upcoming medical meeting.
• The study continues blinded to assess longer-term kidney function over two years, a key determinant for regulatory and commercial outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202609230100BIZWIRE_USPR_____20260922_BW541505) on September 23, 2026, and is solely responsible for the information contained therein.